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In Brief
Clearance of circulating LDL cholesterol
depends primarily on hepatic LDL
receptor (LDLR). Poirier et al. show that
the ER-resident chaperone GRP94
interacts and inhibits PCSK9, a natural
inducer of LDLR degradation. By
preventing PCSK9 binding to LDLR,
GRP94 regulates circulating LDL by
maintaining LDLR protein levels in
hepatocytes.
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Clearance of circulating low-density lipoprotein
cholesterol (LDLc) by hepatic LDL receptors (LDLR)
is central for vascular health. Secreted by hepato-
cytes, PCSK9 induces the degradation of LDLR, re-
sulting in higher plasma LDLc levels. Still, it remains
unknown why LDLR and PCSK9 co-exist within the
secretory pathway of hepatocytes without leading to
complete degradation of LDLR. Herein, we identified
the ER-resident GRP94, and more precisely its
client-binding C-terminal domain, as a PCSK9-LDLR
inhibitory binding protein. Depletion of GRP94 did
not affect calcium homeostasis, induce ER stress,
nor did it alter PCSK9 processing or its secretion but
greatly increased its capacity to induce LDLR degra-
dation. Accordingly, we found that hepatocyte-spe-
cific Grp94-deficient mice have higher plasma LDLc
levels correlated with 80% reduction in hepatic
LDLR protein levels. Thus, we provide evidence that,
in physiological conditions, binding of PCSK9 to
GRP94 protects LDLR fromdegradation likely by pre-
venting early binding ofPCSK9 to LDLRwithin theER.
INTRODUCTION
Familial hypercholesterolemia is a common genetic disorder
affecting 1 in 200–500 people that inherit genetic mutations
mostly in low-density lipoprotein (LDL) receptor (LDLR), apolipo-
protein B-100 (APOB), or proprotein convertase subtilisin kexin
type 9 (PCSK9) loci (Nordestgaard et al., 2013). PCSK9 encodes
for a natural inducer of LDLR degradation (Maxwell and Breslow,
2004), for which patients harboring gain-of-function mutations
have high levels of circulating LDLc (Abifadel et al., 2003).
Conversely, PCSK9 loss-of-function mutations (Cohen et al.,
2005) or pharmacological inhibition significantly increase clear-
ance of plasma LDL particles by hepatocytes (reviewed in Poirier
and Mayer, 2013). Therefore, PCSK9 represents an emerging
lipid-lowering therapeutic target to reduce progression of
atherosclerosis and risk of coronary heart diseases (CHDs).2064 Cell Reports 13, 2064–2071, December 15, 2015 ª2015 The AuPCSK9 is a sterol-regulated gene mainly expressed in liver and
to a lesser extent in kidney and intestine (Maxwell et al., 2003;
Seidah et al., 2003). Within the ER, PCSK9 is autocatalytically
cleaved (Seidahetal., 2003), resulting ina tightly boundsecretable
heterodimeric complex (Cunninghamet al., 2007). Following bind-
ing with PCSK9 (McNutt et al., 2007), LDLR is rerouted from the
cell surface recycling pathway toward late endocytic compart-
ments for degradation (Poirier and Mayer, 2013). In a previous
study, we have identified annexin A2 as an endogenous PCSK9-
binding protein and extrahepatic inhibitor of PCSK9-enhanced
LDLR degradation (Mayer et al., 2008; Seidah et al., 2012). So
far, noother suchendogenousPCSK9 inhibitor hasbeen identified
at the cell surface or within the secretory pathway of hepatocytes.
Under physiological or stress conditions, the ER tightly main-
tains cellular integrity through the help of crucial factors such as
calnexin, calreticulin, glucose-regulated protein 78 (GRP78),
GRP94, and PDIs (Ni and Lee, 2007). GRP94, also known as
gp96, is a highly abundant ER-resident protein recognized pri-
marily as a luminal molecular chaperone but also as a potent cal-
cium- and peptide-binding protein (Lee, 2014). Unlike GRP78,
functional studies revealed that folding and secretion of a very
restrictive number of client proteins were solely dependent on
GRP94 (Marzec et al., 2012). In addition, folding of particular pro-
teins can be driven by private chaperones. Indeed, Boca/Mesd
(Culi and Mann, 2003) and receptor-associated protein (RAP)
(Bu et al., 1995) were identified as specificmolecular chaperones
for LDLR family members that allow for their proper folding and
prevent early interaction with their ligands within the secretory
pathway.
Whereas the liver is by far the richest source of PCSK9, it re-
mains intriguing why hepatic LDLR remains abundant and not
completely degraded by PCSK9. Therefore, we hypothesized
that PCSK9 interacts with one or more yet unidentified protein(s)
to prevent early LDLR binding and degradation under physiolog-
ical conditions.
RESULTS AND DISCUSSION
Identification of GRP94 as an Endogenous PCSK9-
Binding Protein
To identify interacting proteins, PCSK9 was immunoprecipitated
(IP) under both physiological (Figure 1A) or overexpressedthors
Figure 1. Identification of PCSK9-Interacting Proteins
(A and B) Silver staining of proteins immunoprecipitated (IP) with endogenous PCSK9 from HepG2 cells (A) or with overexpressed V5-tagged PCSK9 or PCSK9-
DCTD-V5 from HepG2 or Huh-7 cells (B). Indicated proteins (arrows) were identified by mass spectrometry (see also Figure S1).
(C–E) Immunoblots (IBs) showing coIP of endogenous GRP94 or GRP78 with PCSK9 andmutants thereof from HepG2 or Huh-7 cells transfected with V5-tagged
constructs, as indicated. Asterisks indicate non-specific bands.
(F) IB showing coIP of endogenous PCSK9 with GRP94 or GRP78 from Huh-7 cells transfected with siRNAs against GRP94 or GRP78.
(G) Confocal immunofluorescence microscopy of endogenous PCSK9, GRP94, and LDLR in Huh-7 cells.
(H) Double immunogold localization of GRP94 (6-nm gold particles, arrowheads) and PCSK9 (12-nm gold particles, arrows) in normal human liver tissue.
Colocalization events (encircled) in the rough ER (RER) are emphasized (see also Figure S2).
Data are representative of at least three independent experiments.
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Figure 2. GRP94 Is Not an Obligatory Chaperone for PCSK9
(A) HepG2 cells were incubated for 18 hr with 0 (DMSO), 1, or 5 mM geldanamycin. PCSK9 (lysates and conditioned media) and EGFR (positive control for
geldanamycin) protein levels were analyzed by IB, quantified and normalized over b-actin.
(B) IP of overexpressed PCSK9-V5 or its D374Ymutant from cell lysates of HEK293 cells transfected either with non-targeting siRNAs () or with siGRP94 (+) and
analyzed by IB as indicated.
(C) HepG2 cells were incubated for 18 hr with conditioned media derived from HEK293 cells prepared in (B) (dotted line) and analyzed by IB as indicated. LDLR
levels were quantified and normalized over b-actin (bottom panel).
Data are representative of at least three to four independent experiments. Bars and data from gel quantifications are means ± SD. *p < 0.05; **p < 0.01;
***p < 0.001.(Figure 1B) conditions from human hepatic HepG2 or Huh-7
cells. Co-interacting proteins were separated by SDS-PAGE
and highlighted by silver staining. Mass spectrometry data
from the excised bands revealed human GRP94 as the major
100-kDa migrating protein in complex with PCSK9 in both
conditions (Figures 1A, 1B, S1A, and S1B). The analysis also
revealed GRP78 as the major 76-kDa protein interacting
with overexpressed PCSK9-V5 together with the uncleaved
proPCSK9 precursor present in the ER (Figures 1B and S1B).
Independently of its C-terminal Cys/His-rich domain (CTD or
CHRD), immunoblotting confirmed that PCSK9-V5, but not
LDLR-V5, specifically interacts in complex with GRP94 and
GRP78 (Figure 1C). GRP94 and GRP78 also interacted with
the catalytically inactive PCSK9-H226A-V5 mutant (Figure 1D)
retained in the ER (Seidah et al., 2003). However, both
proPCSK9-V5 and mature PCSK9-V5 were IP using either anti-
GRP94 or anti-GRP78 (Figure 1E), suggesting that the interac-
tion of PCSK9 with those chaperones might not be exclusively
linked to zymogen activation and/or folding of PCSK9 during
de novo synthesis.
As previously reported (Jansen et al., 2012), we observed a
slight interaction between GRP94 and GRP78 (Figure 1E). To
delineate the interdependence of GRP78 and GRP94 in PCSK9
complex formation, PCSK9 was IP following siRNA-mediated
knockdown (KD) of GRP78 or GRP94 (Figure 1F). The data
showed that endogenous GRP78 interacted with PCSK9 only
upon GRP94 KD and that GRP78 is not an intermediate in the
PCSK9-GRP94 complex formation (Figure 1F; siGRP78). In
agreement with coIP experiments, endogenous PCSK9 and2066 Cell Reports 13, 2064–2071, December 15, 2015 ª2015 The AuGRP94, but not LDLR, co-localized in Huh-7 cells (Figure 1G)
and were found associated in the ER of normal human hepato-
cytes (Figures 1H and S2), supporting their interaction in physio-
logical conditions. As compared to GRP94, GRP78 has a wide
variety of client proteins and plays pivotal roles in the unfolded
protein response associated to ER stress in addition to being
an anti-apoptotic and pro-proliferative regulator (Lee, 2014).
Indeed, the absence of GRP94 did not affect cell viability or
the general expression of surface protein in isolated mammalian
cells (Randow and Seed, 2001). At this point of the study, we
consequently decided to focus our work on the specific role of
GRP94 on PCSK9 based on the above identification of hepatic
GRP94 as an endogenous PCSK9 intracellular binding protein.
GRP94 Is Not an Essential Molecular Chaperone for
PCSK9
Next, we wanted to determine whether GRP94 is required for
PCSK9 synthesis and processing by treating HepG2 cells with
geldanamycin (GA), a small molecule competitive inhibitor of
the N-terminal ATP-binding site of GRP94 (Stebbins et al.,
1997). Whereas GA affects EGFR levels (Supino-Rosin et al.,
2000), it did not perturb intracellular proPCSK9 to PCSK9
autocatalytic activation and PCSK9 secretion (Figure 2A),
suggesting that GRP94 activity is dispensable for PCSK9 pro-
cessing. To further substantiate these observations, HEK293
cells were transfected with siRNAs against human GRP94
together with PCSK9-V5 or its high LDLR affinity gain-of-function
D374Y mutant (Figure 2B; reviewed in Poirier and Mayer, 2013).
Both WT and PCSK9-D374Y mutant similarly and specificallythors
interacted with GRP94 as clearly demonstrated following KD of
GRP94 (Figure 2B; IP:V5; IB:GRP94). Consistent with enzymatic
inhibition of GRP94 (Figure 2A), KD of GRP94 did not alter
PCSK9 protein levels, autocatalytic cleavage, furin-regulated
processing (PCSK9-DN218; Benjannet et al., 2006), or its secre-
tion (Figure 2B; Cond. Media), and PCSK9 maintained its full
capacity to induce LDLR degradation following media swap on
naive HepG2 cells (Figure 2C). Therefore, we conclude that
GRP94 is not an essential chaperone for PCSK9 in immortalized
mammalian cells.
Hepatic GRP94 Controls Circulating LDLc by
Maintaining LDLR Protein Levels
Hepatocytes regulate clearance of plasma LDLc via cell surface
LDLR in addition to being the main cell type expressing PCSK9
(Goldstein and Brown, 1987; Seidah et al., 2003). Accordingly,
floxed-Grp94 mice were crossed with albumin-Cre transgenic
mice to generate hepatocyte-specific Grp94-deficient mice
(cGrp94f/f mice; Chen et al., 2014). Similar to Ldlr-deficient
mice (Poirier et al., 2009), circulating PCSK9 levels were elevated
in the plasma of cGrp94f/f mice (Figure 3A), which substantiate
in vivo that GRP94 is not an obligatory chaperone for PCSK9
processing and secretion by hepatocytes. In parallel, we also
observed a 14-fold increase in circulating LDLc in cGrp94f/f
mice (Figure 3A, bottom panel). Whereas LdlrmRNA expression
was not affected (not shown), LDLR protein levels were severely
decreased in livers of cGrp94f/fmice (Figure 3B), reminiscent of
PCSK9 overexpression phenotype (Maxwell and Breslow, 2004).
Importantly, we did not observe any significant difference for
other cell surface transmembrane proteins such as P-cadherin
and CD36 in livers of cGrp94f/f mice (Figure 3B), demonstrating
that GRP94 regulates LDLc by modulating LDLR protein levels.
GRP94 Protects LDLR from PCSK9-Induced
Degradation
Next, we questioned whether the observed effect on LDLR could
be related to ER stress or calcium disturbance asGRP94 is a cal-
cium-binding protein and has been functionally correlated with
the unfolded protein response (Ni and Lee, 2007). Overnight
treatment with thapsigargin (TG), a sarco/ER Ca2-ATPase inhib-
itor and ER stress inducer, in HEK293 cells or mouse embryonic
fibroblasts (MEFs) significantly reduced LDLR levels (Figures 3C
and 3D) without affecting overexpressed PCSK9 processing and
secretion (Figure 3C). In contrast, GRP94 KD did not affect intra-
cellular ER Ca2+ homeostasis (Figure 3E) and did not alter LDLR
protein levels in naturally PCSK9-deficient HEK293 cells (Seidah
et al., 2003; Figure 3F) as compared to PCSK9-rich hepatocytes
of cGrp94f/f mice (Figures 3B and 3D). Moreover, whereas TG
induced expression of GRP78 and ER stress marker CHOP in
MEFs, a mild compensatory increase in GRP78 (Chen et al.,
2014) but no activation of ER stress were observed in livers of
cGrp94f/f (Figure 3D). Together, these data imply a direct
involvement of PCSK9 rather than chaperoning or calcium-buff-
ering effects of GRP94 on LDLR.
To test whether GRP94 is required to maintain LDLR protein
levels in the presence of PCSK9, HepG2 cells were transfected
with cDNA constructs encoding PCSK9-mCherry and LDLR-
EGFP. As shown in Figure 3G, LDLR-EGFP is well expressedCell Repat the cell surface and co-localized with PCSK9-D374Y-mCherry
(Figure 3H, left panels), the latter preserving its capacity to
induce LDLR degradation (Figure 3H, right panels). Interestingly,
KD of GRP94 rendered LDLR much more sensitive to PCSK9-
induced degradation (Figure 3I, lane 5 and right top panel).
Moreover, the proteasome inhibitor MG132 did not block
PCSK9-induced LDLR degradation following KD of GRP94,
eliminating rerouting of the PCSK9/LDLR complex to the ER-
associated degradation pathway (Figure 3I, lane 6 and right
bottom). Therefore, GRP94 could prevent PCSK9 binding to
LDLR and thus limit its subsequent degradation.
Inhibitory Effects of GRP94-CBD-CT Domain on PCSK9-
Induced LDLR Degradation
It was reported that a 27-aa C-terminal hydrophobic loop struc-
ture within the GRP94 client-binding domain (CBD) (aa 652–678;
Figure 4A) is important for folding and interaction with Toll-like
receptors and integrins (Wu et al., 2012). Deletion or alanine-
scan mutations in the CBD of GRP94 did not alter its overall
structure or its ATPase activity but prevented interaction with
its client proteins (Wu et al., 2012). Similarly, we generated sec-
retable HA-tagged cDNA constructs of human GRP94, lacking
its ER-retention C-terminal KDEL sequence, in which critical
CBD residues were mutated to alanine (AA1 and AA2, high-
lighted in blue and red, respectively; Figure 4B). Although ex-
pressed at similar levels to WT, mutations within CBD domain
(AA1 or AA2) abrogated binding to PCSK9 (Figure 4B). Next,
we truncated the whole N-terminal enzymatic domain, resulting
in a small secretable 20-kDa protein encoding the CBD and
CT domains sufficient for interaction with client proteins (Wu
et al., 2012). Whereas the CBD-CT construct was 5-fold less
produced and secreted by HEK293 cells, its interaction with
PCSK9 was significantly enhanced as compared to full-length
(FL) GRP94 (Figure 4C), reinforcing the major role of CBD for
GRP94-PCSK9 interaction.
Next, we used purified or secretable GRP94 or its CBD-CT
domain as surrogates to intracellular GRP94 to test directly for
the inhibition of PCSK9. Confocal microscopy revealed that
PCSK9-mCherry endocytosis was significantly reduced in
LDLR-EGFP-expressing cells in the presence of recombinant
GRP94 (Figure 4D). Although HepG2 cells secrete a small
amount of endogenous GRP94 (5 nM; Figure 4E, lane 1; Mang-
rum et al., 2015), immunoblot data revealed that PCSK9-induced
LDLR degradationwas reversed in a dose-dependentmanner by
addition of GRP94 (Figure 4E, lanes 2–6). These data demon-
strate that exogenous GRP94 efficiently inhibits PCSK9-induced
LDLR degradation likely by blocking PCSK9 interaction and
LDLR-mediated internalization and also suggest that GRP94
could block the PCSK9-LDLR interaction in the ER. In accor-
dance with apparent increased affinity of PCSK9 for CBD-CT
as compared to FL GRP94 (Figure 4C), PCSK9 and CBD-CT
were completely co-localized in a diffuse structure reminiscent
of the ER (Figure 4F, solid arrows) and in the perinuclear Golgi-
like compartment (Figure 4F, dashed arrows), whereas PCSK9
and FL GRP94 mainly co-localized in the ER-like compartment.
Similar to recombinant GRP94 (Figure 4E), overexpression of
secretable FL GRP94 or CBD-CT significantly blocked LDLR
degradation induced by PCSK9 in Huh-7 (Figure 4G) andorts 13, 2064–2071, December 15, 2015 ª2015 The Authors 2067
Figure 3. Absence of GRP94 Increases LDLR Degradation by PCSK9
(A) Plasma PCSK9 levels (top panel; Pcsk9/ plasma; negative control) and lipoprotein cholesterol profiles (bottom panel) from WT and cGrp94f/f mice were
analyzed as described in Supplemental Experimental Procedures.
(B) IB analysis of hepatic LDLR, GRP94, P-cadherin, CD36, and b-actin in WT and cGrp94f/f mice.
(C) IB of thapsigargin-treated (16 hr) HEK293 cells transfected without () or with PCSK9-V5.
(D) IB of LDLR, GRP94, GRP78, CHOP, and P-cadherin in WT and cGrp94f/f mice and thapsigargin-treated (1 or 16 hr) MEFs.
(E and F) Thapsigargin-sensitive Ca2+ stores were monitored by live-cell confocal microscopy, and proteins were analyzed by IB in HEK293 cells transfected with
non-targeting siRNAs () or siGRP94 (+) or treated with thapsigargin (16 hr; herein used as ER Ca2+-depleted condition) as indicated.
(G–I) Confocal microscopy of intracellular (G, top panels) and cell surface LDLR-EGFP (z stack reconstruction shown in G, lower panel) and its co-localization with
PCSK9-mCherry (PCSK9-mC; H) in HepG2 cells under basal conditions or following transfection with either non-targeting siRNAs () or with siGRP94 (+) in the
absence () or presence of MG132 in HEK293 cells (I, right panels). The scale bars represent 20 mm. Corresponding total protein levels were analyzed by IB as
indicated (H, right panels, and I, left panels).
All data are representative of at least three independent experiments. Data are means ± SD. **p < 0.01; ***p < 0.001.
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Figure 4. GRP94-CBD-CT Domain Inhibits PCSK9-Induced LDLR Degradation
(A–C)Mapping of the PCSK9-GRP94-interacting domain. GRP94 structure was extracted from PDB: 2O1V usingMacPymol software, and the CBD-CT domain is
emphasized (A, middle and right panels). IP of PCSK9-V5 fromHEK293 cells co-transfected without () or with GRP94-DKDEL-HA (B and C), its alanine scanning
mutants (AA1, blue, or AA2, red; B), or its CBD-CT domain (C) was analyzed by IB as indicated. Data are representative of at least three independent experiments.
(D) Internalization of PCSK9-mCherry in LDLR-EGFP-expressing HepG2 cells in the absence or presence of recombinant GRP94 was analyzed by confocal
microscopy. The scale bar represents 20 mm. Data are representative of at least three independent experiments.
(E) HepG2 cells were incubated overnight without or with recombinant PCSK9 together with increasing concentrations of recombinant GRP94. Protein levels in
cells and media were analyzed by IB as indicated. Data are representative of at least three independent experiments.
(F and G) Huh-7 cells were transfected without or with PCSK9-V5, full-length GRP94-DKDEL-HA (FL), or its CBD-CT domain. Subcellular localization was
visualized by confocal microscopy (F; scale bar, 20 mm), and protein levels were analyzed by IB, as indicated (G). Data are representative of at least three in-
dependent experiments.
(H) HepG2 cells were transfected with non-targeting siRNAs () or siPCSK9 for 48 hr and incubated 18 hr with 2 mg/ml recombinant CBD-CT-HA-His6. Protein
levels in lysates and media were analyzed by IB as indicated. Data were analyzed in duplicate.
(I) The inhibitory effect of rhCBD-CT-HA-His6 on PCSK9-LDLR (EGF-AB) binding was analyzed by in vitro competitive assay. Coomassie staining of rhCBD-CT-
HA-His6 is shown. Data represent means of two independent experiments analyzed in duplicate ± SD. *p < 0.05; **p < 0.01; ***p < 0.001.
Data from gel quantifications (normalized over b-actin; E, G, and H) are means ± SD. **p < 0.01.HepG2 cells (data not shown). Furthermore, addition of recombi-
nant CBD-CT significantly increased total LDLR protein levels in
a PCSK9-dependent manner (Figure 4H), most likely via a direct
competition with LDLR-EGF-A domain for PCSK9 (Figure 4I).
Overall, these data demonstrated that PCSK9-GRP94 complex
formation, andmore specifically its CDB-CT domain, has a direct
inhibitory effect on the binding of PCSK9 to LDLR and its subse-
quent degradation.
Indicative of its very restrictive selection of client proteins, tis-
sue- or cell-type targeted deletions of Grp94 have underlined its
specific roles in the maintenance of organ homeostasis, innate
and adaptive immunity, and cancer progression (Lee, 2014).
In the present study, we identified GRP94 as an ER-resident
PCSK9-interacting protein (Figures 1A, 1G, and 1H) and inhibitor
of PCSK9-LDLR complex formation (Figure 4I). Accordingly, he-Cell Reppatocyte-specific deletion of Grp94 severely increased plasma
PCSK9 and LDLc levels (Figure 3A), which is correlated with
almost undetectable hepatic LDLR protein levels (Figure 3B).
Moreover, we showed that LDLR was much more sensitive to
degradation in the absence of GRP94 in PCSK9-expressing cells
and liver (Figures 3B, 3I, and 4G). As a physiological mechanism,
we propose that GRP94 regulates circulating LDLc and sustains
LDLR protein levels likely by preventing PCSK9-LDLR binding in
the ER of hepatocytes.
We previously identified annexin A2 as an endogenous
PCSK9-CTD-binding protein and potent extrahepatic inhibitor
of PCSK9-mediated LDLR degradation (Mayer et al., 2008;
Seidah et al., 2012). In contrast, GRP94 is highly expressed in he-
patocytes and its interaction with PCSK9 involves the catalytic
domain and directly competes for binding with LDLR-EGF-Aorts 13, 2064–2071, December 15, 2015 ª2015 The Authors 2069
domain (Figure 4I). Molecular characterization revealed that
GRP94 is not an obligatory chaperone for PCSK9 and that, unlike
CBD domain, the GRP94 N-terminal domain, important for
folding of its client proteins, is not involved in PCSK9 interaction
and subsequent inhibition of LDLR degradation. In terms of func-
tional therapeutics, one may think that the presence of GRP94,
or preferably CBD-CT or CBD that lacks its chaperoning domain,
in the plasma would not interfere with the physiological functions
of GRP94 normally occurring in the ER. Therefore, as demon-
strated in this study, GRP94 and fragments thereof may be
used therapeutically to target PCSK9 and block binding to
LDLR, preventing its intracellular degradation and, hence,
reducing LDLc and the risk of CHD.
EXPERIMENTAL PROCEDURES
A detailed description of all methods can be found in the Supplemental Exper-
imental Procedures. All animal studies were approved by the University of
Southern California Institutional Animal Care andUseCommittee and theMon-
treal Heart Institute Animal Care and Ethical Committee. Hepatocyte-specific
Grp94-deficient male mice (cGrp94f/f) were obtained by crossing Alb-Cre with
Grp94f/f mice (Chen et al., 2014). Littermates lacking Alb-Cre served as WT
controls. Blood samples were collected by cardiac puncture, and livers were
dissected and snap frozen in liquid nitrogen for further analyses as indicated.
Cell culture, plasmid constructions, and transfections were performed accord-
ing to standard protocols as described in the Supplemental Experimental Pro-
cedures. For IP, cells were lysed in RIPA buffer without or with SDS and V5 or
HA-tagged proteins, PCSK9, GRP94, or GRP78 were immunoprecipitated
with indicated antibodies. PCSK9-interacting proteins were identified by
mass spectrometry. For western blot analyses, cells and tissue samples
were lysed in RIPA buffer and proteins were separated by SDS-PAGE, trans-
ferred to nitrocellulose membranes, and incubated with indicated antibodies.
Human PCSK9 was obtained from conditioned media of HEK293T transiently
transfected with His6-tagged PCSK9. GRP94-CDB-CT-DKDEL-HA-His6 was
produced following IPTG induction in T7 competent E. coli and recovered
from bacterial lysates. Both proteins were purified by affinity followed by
size exclusion chromatography and used for cell-based PCSK9 competitive
assays. Solid phase PCSK9-LDLR(EGF-AB) in vitro competitive binding assay
(Circulex; cat. no. CY-8150) with recombinant CBD-CT-HA-His6 was per-
formed according to manufacturer’s recommendations. All data are presented
as mean ± SD and are representative of at least three independent experi-
ments analyzed in duplicate. Protein bands from SDS-PAGE were quantified
and normalized using GelEval software. Statistical analysis was performed us-
ing Student’s t test. p < 0.05 was considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2015.11.006.
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